lymphoma

[Proceedings of the National Academy of Sciences of the United States of America] To advance the development of natural killer (NK)-based therapies, scientists developed a functional screen to rapidly identify antibodies that can activate NK cells. They displayed antibodies on a mammalian target cell line and probed their ability to stimulate NK cell-mediated cytotoxicity.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.

[Nature Medicine] Ten of 16 patients with large B cell lymphoma with progressive disease after CAR19 treatment had absent or low CD19.

[Molecular Therapy-Methods & Clinical Development] Investigators found that high CD14+ cell content posed a challenge for manufacturing CAR T cells especially in patients with non-Hodgkin’s lymphoma and multiple myeloma due to the non-specific phagocytosis of the magnetic beads used to activate CD3+ T cells.

[npj Precision Oncology] Researchers provided in-depth investigation of copy number alteration heterogeneity in phenotypically characterized circulating tumor cells at resistance to Anaplastic Lymphoma Kinase (ALK)-tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.

[Leukemia] In this open-label, single-arm Phase I/II trial, 87 patients with recurrent/refractory non-Hodgkin lymphoma received an infusion at doses of 0.5 × 106–8 × 106 TanCAR7 T cells per kilogram of body weight after conditioning chemotherapy.